Global HIV Diagnostics Market: Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis 2012-2016 and Forecast 2017-2023

November 2017 | 216 pages | ID: G562A9C9539EN
Precision Business Insights (PBI)

Abstracts

Acquired immune deficiency syndrome (AIDS) is a retroviral infectious disease caused by human immunodeficiency virus (HIV). HIV attacks the body immune system ideally CD4 cells (T cells), which helps the immune system to fight infections. HIV spreads through body fluids i.e. blood donation and imparting needles to somebody who is HIV infected, and sexual interactions. If HIV is not treated the opportunistic infections like tuberculosis or cancer take advantage of very weak immune system and causes AIDS. The HIV diagnosis can be done by viral load test, saliva test, and blood test. Most accurate test results can obtained by enzyme linked immunosorbent assay (ELISA) test initial stages and western blot method on later stages. Currently, there was no effective cure exists for HIV, but with proper medical care, it can be controlled.

HIV diagnostics market is driven by global increase in prevalence of HIV/AIDS, rise in number of blood transfusions and blood donations, benefits of point-of-care instruments & kits in which patients can be diagnosed even outside the laboratory setting, and increasing government initiatives. In addition, technological advancements in disease diagnostic tests, improvement and commercialization of novel, regulatory approved point of care and rapid CD4, p24 antigen and EID tests are expected to boost the HIV diagnostics market over the forecast period. However, lack of awareness in many undeveloped regions, stringent government regulations and unfavourable reimbursement policies would limit the growth of the market.

HIV Diagnostics Market segmented based on type of test, and end user

Based on type of test, HIV diagnostics market is segmented into

• CD4 count
• Antibody test
• Viral identification
• Viral load
• Others

Based on end-user, HIV diagnostics market is segmented into

• Hospitals
• Diagnostic centers
• Blood banks
• Home care settings

Global HIV diagnosis market is growing at steady state. Government and non-government organizations are also participating in creating and growing awareness related to early HIV diagnosis and available diagnostic tests and equipment. According to WHO, 2015, there is 0.8% prevalence of HIV globally and Sab-Saharan Africa remains most severely affected area with 70% of people for global population. For instance, the unmet requirements in Asia and Africa region for HIV diagnosis, and the government initiatives taken in the region may drive the market for HIV diagnostics. Market players adopting mergers and acquisitions to increase the market position in HIV diagnostics market. In addition, market has a number of pipeline products in accurate and quick diagnosis of HIV few of them are Visitect CD4, Chipcare CD4, and MBIO CD4. Antibody diagnosis test is predominant among the segments. Due to the introduction of point of care products can easily and quickly diagnose disease.

Geographically HIV diagnostics market has been segmented into following regions viz. North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. North America holds dominant revenue share in global HIV diagnostics market, and it is due to rapid adoption of technologically, advanced diagnostic solutions, and growing demand for portable and point of care (POC) diagnostic devices. Furthermore, large pool of patients suffering with HIV and mandatory implementation of HIV screening tests are expected to boost regional penetration of HIV diagnostics. As per the WHO statistics, by the end of 2011, 1.4 Mn people were infected with HIV/AIDS including adults and children. Asia-Pacific expected to be lucrative market for HIV diagnostics, owing to growing patients suffering from HIV/AIDS and increase in awareness among the population related to HIV diagnostics. In the Middle East and Africa region, South Africa has enormous opportunity due to increasing awareness and presence of a large number of infected people. According to UNAIDS report, 2016, 19.4 Mn people in Eastern and South Africa alone living with HIV, and it is more than half of the HIV infected people around the world.

Some of the players in HIV diagnostics market are F. Hoffmann-La Roche AG (Switzerland), Abbott Laboratories (U.S.), Siemens AG (Siemens Healthineers) (Germany), Merck KGaA (Germany) Hologic, Inc. (U.S.), Fisher Bioblock Holding II SNC (Thermo-Fisher Scientific) (U.S.),Becton, Dickinson and Company (U.S.),Alere Inc. (U.S.), and Bio-Rad Laboratories (U.S.) to name a few.

In 2015, bioLytical Laboratories Inc., a leading manufacturer of point-of-care rapid diagnostic tests, received U.S. Food and Drug Administration (FDA) approval of its INSTI HIV Antibody Test for use in detecting antibodies to HIV type 2

REPORT OUTLINE:

• The report provides granular level information about the market size, regional market share and forecast from 2017-2023
• The report covers in-detail insights about the competitor’s overview, key findings and their key strategies
• The report outlines drivers, restraints, challenges, and trends that are currently faced by the industry
• The report tracks recent innovations, key developments and startup’s details that are working in the industry
• The report provides plethora of information about market entry strategies, regulatory framework and reimbursement scenario

Contents

1. EXECUTIVE SUMMARY

2. GLOBAL HIV DIAGNOSTICS MARKET INTRODUCTION

2.1. Global HIV Diagnostics Market– Taxonomy
2.2. Global HIV Diagnostics Market–Definitions
  2.2.1. End User
  2.2.2. Test Type

3. GLOBAL HIV DIAGNOSTICS MARKET DYNAMICS

3.1. Drivers
3.2. Restraints
3.3. Opportunities/Unmet Needs of the Market
3.4. Trends
3.5. Global HIV Diagnostics Market Dynamics – Factors Impact Analysis
3.6. Global HIV Diagnostics Market– Recent Product Launches

4. GLOBAL HIV DIAGNOSTICS MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 – 2023

4.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
4.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
4.3. Market Oppurtunity Analysis

5. GLOBAL HIV DIAGNOSTICS MARKET FORECAST, BY TEST TYPE, 2012 - 2016 AND FORECAST, 2017 - 2023

5.1. CD4 Count
  5.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  5.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  5.1.3. Market Opportunity Analysis
5.2. Antibody Test
  5.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  5.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  5.2.3. Market Opportunity Analysis
5.3. Viral Identification
  5.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  5.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  5.3.3. Market Opportunity Analysis
5.4. Viral Load
  5.4.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  5.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  5.4.3. Market Opportunity Analysis
5.5. Others
  5.5.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  5.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  5.5.3. Market Opportunity Analysis

6. GLOBAL HIV DIAGNOSTICS MARKET FORECAST, BY END USER, 2012 - 2016 AND FORECAST, 2017 - 2023

6.1. Hospitals
  6.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  6.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  6.1.3. Market Opportunity Analysis
6.2. Diagnostic Centers
  6.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  6.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  6.2.3. Market Opportunity Analysis
6.3. Blood Banks
  6.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  6.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  6.3.3. Market Opportunity Analysis
6.4. Home Care Settings
  6.4.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  6.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  6.4.3. Market Opportunity Analysis

7. GLOBAL HIV DIAGNOSTICS MARKET FORECAST, BY REGION, 2012 - 2016 AND FORECAST, 2017 - 2023

7.1. North America
  7.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  7.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  7.1.3. Market Opportunity Analysis
7.2. Europe
  7.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  7.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  7.2.3. Market Opportunity Analysis
7.3. Asia-Pacific
  7.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  7.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  7.3.3. Market Opportunity Analysis
7.4. Latin America
  7.4.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  7.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  7.4.3. Market Opportunity Analysis
7.5. Middle East and Africa
  7.5.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  7.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  7.5.3. Market Opportunity Analysis
7.6. Global HIV Diagnostics Market- Opportunity Analysis Index - By Test Type, By End User, and Region, 2017 – 2023

8. NORTH AMERICA HIV DIAGNOSTICS MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023

  8.1.1. Test Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
    8.1.1.1. CD4 Count
    8.1.1.2. Antibody Test
    8.1.1.3. Viral Identification
    8.1.1.4. Viral Load
    8.1.1.5. Others
  8.1.2. End User Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
    8.1.2.1. Hospitals
    8.1.2.2. Diagnostic Centers
    8.1.2.3. Blood Banks
    8.1.2.4. Home Care Settings
  8.1.3. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
    8.1.3.1. U.S.
    8.1.3.2. Canada
  8.1.4. North America HIV Diagnostics Market- Opportunity Analysis Index - By Test Type, By End User, and Country, 2017 – 2023
  8.1.5. North America HIV Diagnostics Market Dynamics – Trends

9. EUROPE HIV DIAGNOSTICS MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023

  9.1.1. Test Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
    9.1.1.1. CD4 Count
    9.1.1.2. Antibody Test
    9.1.1.3. Viral Identification
    9.1.1.4. Viral Load
    9.1.1.5. Others
  9.1.2. End User Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
    9.1.2.1. Hospitals
    9.1.2.2. Diagnostic Centers
    9.1.2.3. Blood Banks
    9.1.2.4. Home Care Settings
  9.1.3. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
    9.1.3.1. Germany
    9.1.3.2. UK
    9.1.3.3. France
    9.1.3.4. Spain
    9.1.3.5. Italy
    9.1.3.6. Russia
    9.1.3.7. Poland
    9.1.3.8. Rest of Europe
  9.1.4. Europe HIV Diagnostics Market- Opportunity Analysis Index - By Test Type, By Application, By End User, and Country, 2017 – 2023
  9.1.5. Europe HIV Diagnostics Market Dynamics – Trends

10. ASIA-PACIFIC HIV DIAGNOSTICS MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023

  10.1.1. Test Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
    10.1.1.1. CD4 Count
    10.1.1.2. Antibody Test
    10.1.1.3. Viral Identification
    10.1.1.4. Viral Load
    10.1.1.5. Others
  10.1.2. End User Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
    10.1.2.1. Hospitals
    10.1.2.2. Diagnostic Centers
    10.1.2.3. Blood Banks
    10.1.2.4. Home Care Settings
  10.1.3. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn),
Y-o-Y Growth (%), and Market Share (%)
    10.1.3.1. Japan
    10.1.3.2. China
    10.1.3.3. India
    10.1.3.4. ASEAN
    10.1.3.5. Australia & New Zealand
    10.1.3.6. Rest of Asia-Pacific
  10.1.4. Asia-Pacific HIV Diagnostics Market- Opportunity Analysis Index - By Test Type, By End User, and Country, 2017 – 2023
  10.1.5. Asia-Pacific HIV Diagnostics Market Dynamics – Trends

11. LATIN AMERICA HIV DIAGNOSTICS MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023

  11.1.1. Test Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
    11.1.1.1. CD4 Count
    11.1.1.2. Antibody Test
    11.1.1.3. Viral Identification
    11.1.1.4. Viral Load
    11.1.1.5. Others
  11.1.2. End User Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
    11.1.2.1. Hospitals
    11.1.2.2. Diagnostic Centers
    11.1.2.3. Blood Banks
    11.1.2.4. Home Care Settings
  11.1.3. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
    11.1.3.1. Brazil
    11.1.3.2. Mexico
    11.1.3.3. Argentina
    11.1.3.4. Venezuela
    11.1.3.5. Rest of Latin America
  11.1.4. Latin America HIV Diagnostics Market- Opportunity Analysis Index - By Test Type, End User, and Country, 2017 – 2023
  11.1.5. Latin America HIV Diagnostics Market Dynamics – Trends

12. MIDDLE EAST & AFRICA HIV DIAGNOSTICS MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023

  12.1.1. Test Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
    12.1.1.1. CD4 Count
    12.1.1.2. Antibody Test
    12.1.1.3. Viral Identification
    12.1.1.4. Viral Load
    12.1.1.5. Others
  12.1.2. End User Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
    12.1.2.1. Hospitals
    12.1.2.2. Diagnostic Centers
    12.1.2.3. Blood Banks
    12.1.2.4. Home Care Settings
  12.1.3. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
    12.1.3.1. Gulf Cooperation Council (GCC) Countries
    12.1.3.2. Israel
    12.1.3.3. South Africa
    12.1.3.4. Rest of MEA
  12.1.4. MEA HIV Diagnostics Market- Opportunity Analysis Index - By Test Type, By End User, and Country, 2017 – 2023
  12.1.5. MEA HIV Diagnostics Market Dynamics – Trends

13. COMPETITION LANDSCAPE

13.1. Strategic Dashboard of Top Market Players
13.2. Company Profiles (Introduction, Financial Analysis, Drug & Service Offerings, Key Developments, Strategies, and SWOT Analysis)
  13.2.1. F. Hoffmann-La Roche AG (Switzerland)
  13.2.2. Abbott Laboratories (U.S.)
  13.2.3. Siemens AG (Siemens Healthineers) (Germany)
  13.2.4. Hologic, Inc. (U.S.)
  13.2.5. Fisher Bioblock Holding II SNC (Thermo-Fisher Scientific) (U.S.)
  13.2.6. Becton, Dickinson and Company (U.S.)
  13.2.7. Alere Inc. (U.S.)
  13.2.8. Bio-Rad Laboratories (U.S.)

14. RESEARCH METHODOLOGY

15. KEY ASSUMPTIONS AND ACRONYMS